Competing-risks regression models were performed to test the effect of age on CSM in the entire cohort, and for each grade (Gleason score 2–4, 5–7, and 8–10) and stage (pT2, pT3a, and pT3b) sub-cohorts. Advancing age was associated with higher 15-year CSM rates (2.3 vs. ...
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.PubMedGoogle ScholarCrossref 60. Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially...
Prostate cancer is a major disease that threatens men’s health. Its rapid progression, easy metastasis, and late castration resistance have brought obstacles to treatment. It is necessary to find new effective anticancer methods. Ferroptosis is a novel
Prostate cancer (PCa) ranges from an indolent disease to aggressive, castration-resistant prostate cancer (CRPC), associated with a poor prognosis1,2. However, genetic alterations in epithelial cancer cells do not fully explain the different clinical behaviors of this malignancy3,4. Previous studies...
Leur but est d’optimiser la détection du cancer de la prostate mais aussi la discrimination des cancers agressifs afin d’éclairer les décisions de traitement. Summary Widespread screening for prostate cancer has led to an increased incidence, an improved disease specific survival, but also to...
Prostate cancer (PCa) represents a substantial global health concern and a prominent contributor to male cancer-related mortality. The aim of this study is to explore the role of B-type endothelin receptor (EDNRB) in PCa and evaluate its therapeutic pote
Prostate cancer PCAF: p300/CBP associated factor PEITC: Phenethyl isothiocyanate PFS: Progression-free survival PIN: Prostatic intraepithelial neoplasia PLAU : Urokinase plasminogen activator PRC2: Polycomb repressive complex 2 PSA: Prostate-specific antigen PSA-DT: PSA doubling time PTGS2 ...
While the 5-year survival rate of patients with low-grade localized prostate cancer is high, men with metastatic prostate cancer suffer from a 30% 5-year survival rate, as tumors become increasingly difficult to treat [1]. Most patients with advanced metastatic prostate cancer are treated with ...
It is the third leading cause of male cancer deaths in Europe1,2 and second in the USA although an estimated 90% of newly diagnosed cases are local or regional with a 5-year relative survival approaching almost 100%.3 A frequently occurring genetic alteration of prostate tumors is a gene ...
4B), onset of metastatic disease (p = 0.18), or cancer-related survival (p = 0.05). Multivariate analysis Multivariate Cox regression analyses were performed including Gleason Score, surgical margin status, pT stage, pre-operative PSA levels, nuclear p53 IHC, and cytoplasmic survivin ...